Cécile Matthews and Bhavesh Patel were quoted in Pink Sheet regarding their analysis entitled “How do rare disease patient numbers in Germany affect prices for non-oncology orphan drugs?” In Pink Sheet, Matthews and Patel discuss factors to consider when agreeing on a price including benefit ratings, patient populations, and budget impact.
CRA leading the way in analytics
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative...